<p> <b>Full Title</b><br> Protocol OSE2101C302: A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor </p> <p> <b>Study Treatment</b><br> OSE2101, a peptidic cancer vaccine, given in combination with chemotherapeutic agent docetaxel </p> <p> <b>Eligibility/Info</b><br> Participants must have a history of an advanced/metastatic non-small cell lung cancer that has progressed after at least 24 weeks of first line treatment with immunotherapy. </p> <p> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. </p> <p> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br> </p>